(Reuters) - WASHINGTON, March 29 - U.S. health officials withdrew Parkinson's disease drug pergolide from the market on Thursday, citing a history of safety concerns that include potentially fatal heart valve damage.
The Food and Drug Administration decided to pull pergolide, which is sold by generic drug companies and by Valeant Pharmaceuticals International under the name Permax, after reports showed it can cause problems similar to those that triggered the withdrawal of diet drug combination "fen-phen."
Read more at Reuters.com Government Filings News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment